Raul Cordoba/X
Jun 29, 2025, 14:28
Raul Cordoba Highlights Study on Performance of CHA2DS2-VASc and HAS-BLED in Predicting Stroke and Bleeding in Atrial Fibrillation and Cancer
Raul Cordoba, Associate Chief at the Department of Hematology at Jiménez Díaz Foundation, shared a post on X:
“Performance of CHA2DS2-VASc and HAS-BLED in predicting stroke and bleeding in atrial fibrillation and cancer.
“The CHA2DS2-VASc score had good to modest discrimination in haematological cancer AUC = 0.71 (0.66, 0.76), compared with no-cancer AUC = 0.73 (0.72, 0.74)
HAS-BLED discrimination was poor in haematological cancer AUC = 0.59 (0.55, 0.64), compared with no-cancer AUC = 0.61 (0.60, 0.62)”
Title: Performance of CHA2DS2-VASc and HAS-BLED in predicting stroke and bleeding in atrial fibrillation and cancer
Authors: Alyaa M Ajabnoor, Salwa S Zghebi, Rosa Parisi, Darren M Ashcroft, Corinne Faivre-Finn, Mamas A Mamas, Evangelos Kontopantelis
Read the full article.
Stay updated with Hemostasis Today.
-
Sep 1, 2026, 02:41Richard Buka: Win a Trip to ASH or ISTH 2027
-
Sep 1, 2026, 02:38Christian’s Journey to Stability on Avatrombopag – ITP Support Association
-
Sep 1, 2026, 02:35Alexis Guédon: Is IL-6 Pathway Inhibition Reduce Cardiovascular Risk in Giant Cell Arteritis?
-
Aug 31, 2026, 17:11Chokri Ben Lamine: Early Recognition and Immediate Treatment of Catastrophic APS
-
Aug 31, 2026, 17:06Nikolaos Ktenopoulos: COMPASS-ARTeCAT Trial Highlights Arterial Thrombosis in Patients With Cancer
-
Aug 31, 2026, 17:01Mark Kaplan: Same LDL-C, Different Coagulation, Different Outcomes, in FH
-
Aug 31, 2026, 16:55Kemal Karaagac: Milvexian Did Not Reduce Ischemic Events but Did Not Increase Fatal Bleeding
-
Aug 31, 2026, 16:47Improving Outcomes in AF-Related Stroke Beyond Anticoagulation at ESC 2026 – ESO
-
Aug 31, 2026, 16:39Shariq Shamim: Are We Going to Start DOAC post TAVI not DAPT?